The ABCD3 Knockout HAP1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the ABCD3 gene within the near-haploid HAP1 cell line. This product provides a robust loss-of-function model for investigating peroxisomal biology and lipid metabolism. The polyclonal format consists of a heterogeneous pool of cells carrying various gene-editing events, allowing for unbiased functional studies without the constraints of clonal isolation. Ideal for researchers requiring a versatile knockout system, these cells support a wide range of experimental approaches in functional genomics and disease modeling.
The HAP1 cell line is a male-derived near-haploid human hematopoietic cell line originally isolated from the KBM-7 chronic myeloid leukemia cells. Its near-haploid karyotype simplifies functional genomics by reducing genetic redundancy, enabling straightforward knockout generation and facilitating clear genotype-phenotype analyses. This feature, combined with its leukemic origin, makes HAP1 a valuable platform for studying both fundamental cellular processes and cancer biology, particularly in the context of CRISPR-based screens.
ABCD3 encodes a peroxisomal ATP-binding cassette transporter that mediates the import of very long-chain fatty acids, branched-chain fatty acids, and bile acid intermediates into peroxisomes for ??-oxidation. Transcriptionally regulated by PPAR??, PPAR??, and their heterodimeric partner RXR, ABCD3 plays a central role in maintaining lipid homeostasis and preventing toxic accumulation of these substrates. It functionally interacts with PEX19 for peroxisomal membrane targeting and operates in concert with other peroxisomal transporters such as ABCD1. Downstream, the imported substrates are catabolized by the ??-oxidation machinery involving ACOX1, DBP, and SCPx, generating acetyl-CoA and influencing reactive oxygen species levels. The peroxisomal import of these enzymes relies on PEX5 and PEX7, connecting ABCD3 to broader peroxisome biogenesis pathways. Loss of ABCD3 disrupts this network, leading to peroxisomal dysfunction and altered PPAR?? signaling, which perturbs expression of multiple peroxisomal genes.
In the HAP1 cellular context, ABCD3 knockout effectively models peroxisomal disorders such as Zellweger spectrum disorder, characterized by very long-chain fatty acid accumulation. The near-haploid nature of HAP1 cells ensures that gene disruption yields clear phenotypic changes, while the leukemic background allows exploration of lipid metabolism in cancer, including hepatocarcinogenesis. This model is particularly suited for investigating how peroxisomal dysfunction contributes to metabolic reprogramming and drug sensitivity in hematopoietic malignancies. The polyclonal knockout approach maintains population diversity, reducing artifacts from single?clone selection.
These polyclonal knockout cells are ideally suited for peroxisomal disorder modeling, lipid metabolism studies, CRISPR-based functional genomics, and drug sensitivity profiling. Researchers can employ western blotting to confirm ABCD3 loss, immunofluorescence for peroxisome markers (e.g., PEX14) to assess organelle integrity, fatty acid oxidation assays to measure metabolic flux, lipidomics for profiling lipid species, cell viability assays under fatty acid supplementation, and RT-qPCR for peroxisomal gene expression changes. This comprehensive suite of applications makes the ABCD3 Knockout HAP1 Polyclonal Cells a versatile tool for dissecting peroxisomal function and its implications in disease. For further information, please contact Ascent Research.
